{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:03:06Z","timestamp":1780329786148,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.msard.2026.107202","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:44:07Z","timestamp":1776120247000},"page":"107202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness and safety of ocrelizumab in relapsing-onset multiple sclerosis: A nationwide real-world study from Slovakia"],"prefix":"10.1016","volume":"110","author":[{"given":"Marianna","family":"Vitkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmila","family":"Szilasiov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Fedi\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edita","family":"Kahancov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavol","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katar\u00edna","family":"Kole\u0148\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ria","family":"Kia\u010dikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Dziakov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bil\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Laurincov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Koleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavom\u00edra","family":"Kov\u00e1\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Han\u010dinov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bullov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Kantorov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Karl\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2182-987X","authenticated-orcid":false,"given":"Darina","family":"Slez\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107202_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neurol.2015.10.006","article-title":"Epidemiology of multiple sclerosis","volume":"172","author":"Leray","year":"2016","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2026.107202_bib0002","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107202_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107202_bib0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in primary progressive Multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107202_bib0005","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1177\/1352458516653667","article-title":"Observational data: understanding the real MS world","volume":"22","author":"Kalincik","year":"2016","journal-title":"Mult Scler J"},{"issue":"8","key":"10.1016\/j.msard.2026.107202_bib0006","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1007\/s10072-024-07449-0","article-title":"Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario","author":"Lorefice","year":"2024","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107202_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40940-w","article-title":"Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort","volume":"13","author":"Ingwersen","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2026.107202_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1500763","article-title":"Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study","volume":"15","author":"Fernandes","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107202_bib0009","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1212\/NXI.0000000000000719","article-title":"Ocrelizumab initiation in patients with MS: a multicenter observational study","volume":"7","author":"Ellwardt","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107202_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116973","article-title":"Real world application of ocrelizumab in multiple sclerosis: single-center experience of 128 patients","volume":"415","author":"Prockl","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107202_bib0011","article-title":"Real-world results of Ocrelizumab treatment for primary progressive multiple sclerosis","volume":"2020","author":"Daniels","year":"2020","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.msard.2026.107202_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105570","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: real\u2011world experience of two Swiss multiple sclerosis centres","volume":"86","author":"Diem","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107202_bib0013","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s13760-024-02572-3","article-title":"Real-world effectiveness, safety and immunogenicity of ocrelizumab in Turkish multiple sclerosis patients: a single-center experience for 4-year follow-up","volume":"124","author":"Erdogan","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2026.107202_bib0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40801-025-00486-x","article-title":"Long-term evaluation of effectiveness and immunological implications of ocrelizumab in a real-world cohort","volume":"12","author":"Guerra","year":"2025","journal-title":"Drugs Real. World Outcomes."},{"key":"10.1016\/j.msard.2026.107202_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104109","article-title":"safety and patient-reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: final results from the PRO-MSACTIVE study","volume":"68","author":"Manchon","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107202_bib0016","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/acn3.51282","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population","volume":"8","author":"Fernandez-Diaz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107202_bib0017","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/0004-282x-anp-2020-0339","article-title":"Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America","volume":"79","author":"Rojas","year":"2021","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2026.107202_bib0018","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/1352458517703193","article-title":"No evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107202_bib0019","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/acn3.51282","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population","volume":"8","author":"Fernandez-Diaz","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826002385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:25:02Z","timestamp":1780327502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826002385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"alternative-id":["S2211034826002385"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107202","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of ocrelizumab in relapsing-onset multiple sclerosis: A nationwide real-world study from Slovakia","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107202"}}